Jubilant Life Sciences Company has collaborated with Janssen Pharmaceutical for a drug discovery alliance for three years, targeting neuroscience area. The stock of Jubilant was at Rs. 198 that is Rs 19.80 high.

The stock of Jubilant has gone up by 11.08%, the shares have gone up by Rs 19.75 to Rs 197.95. Earlier, it was trading with 562,432 shares, whereas its 5-day average was 33,740 shares that was an increase of 1,566.98%.

Earlier, an average of two week was notified as 0.23 lakh shares but the trading has gone up to 4.7 lakh shares now.

The agreement includes transferring of current work on the chosen drug discovery targets by Janssen to the co-partner. Jubilant will research and will provide the facts relating to the disease before the symptoms become evident to Janssen and therefore, the later Company will work on further development.

Jubilant Global Drug Discovery & Development CEO & President Sri Mosur stated that the company is satisfied with the collaboration with the best pharmaceutical research and Commercialization Company. This collaboration will help in the area of neuroscience, along with the India-based research centers. He said that they are expecting for an effective outcome with this resourceful alliance.